 Welcome back to Vegas, baby. Lisa Martin here with theCUBE. We are live at Caesars Forum, covering Snowflake Summit 22. This is day two of our wall-to-wall coverage on theCUBE you won't want to miss. We've got an exciting customer story to talk to you about next, with Novartis and Snowflake. Please welcome two guests to theCUBE, Loic Girant, Global Head Delivery, Global Head Digital Delivery Novartis. I hope I got the name right. Yes, hi, thank you. I did my best. Absolutely. Jesse Cugliata also joins us, Global Industry Lead Healthcare and Life Sciences at Snowflake. Welcome with theCUBE, gentlemen. Thank you for having us. Good morning. So it was great to hear Novartis is a household word now, especially with what's gone on in the last two years. Had a chance to see the keynote yesterday, heard Novartis mention in terms of a massive outcome that Snowflake is delivering, that we're going to get to. But Loic, talk to us about Novartis, Global 500 organization. You rank among the world's top companies investing in R&D, the massive portfolio, and you're reaching nearly 800 million patients worldwide. That's huge, but there's been a lot of change in the healthcare and life sciences industry, especially recently. Talk to us about the industry landscape. What are you seeing? So, I mean, as you describe, R&D Novartis is one of the top life science company in the world. We are number three. We operate in 150 countries and we have almost 120,000 employees. We actually, our purpose is actually to re-imagine medicine through the use of data science and technology to extend people's life. And we really mean it. I think, as you mentioned, we treat 800 million patients per year with our drugs and we expect to treat more than a billion patients in near time soon. So, over the last few years, especially during COVID, our transformation or digital transformation help us to accelerate the drug discovery and then the commercialization of our drug to markets. As it was mentioned in the keynote yesterday, we have actually been able to reduce our time to markets. It used to take us up to 12 years and cost around $1.2 billion to discover and commercialize drug. And now we've actually used technology like Snowflake. We have been able to reduce by two to three years, which ultimately is a benefit for our patients. Absolutely. Well, we're talking about life and death situations. Talk about, you mentioned Novartis wants to re-imagine medicine. What does that look like? Where is data in that? And how is Snowflake an enabler of re-imagining medicine? Data is a core of our assets. It's a core of enterprise process. So, if you look at our enterprise, we are using data from the research through drug development in a manufacturing process and how do we market and sell our product through HCPs and distributors to reach our patients. If you build that for our digital transformation, we have created this integrated data ecosystem where Snowflake is a core component. And through that ecosystem, we are able to identify compounds and cohorts, perform clinical trials and engage HCPs and HCOs so they can prescribe our drugs to serve our patient needs. Justice, let's bring you into the conversation. Snowflake recently launched its healthcare and life sciences data cloud. I believe that was back in March. It was. Just a couple of months ago. Talk to us about the vertical focus. Talk to us about what this healthcare and life sciences data cloud is aiming to help customers like Novartis achieve. Well, as you mentioned there, Snowflake has made it a real pivot to kind of focus on the various different industries that we serve in a new way. I think historically we've been engaged in really all of the industries across the major sectors where we participate today. But historically we've been often engaging with the Office of IT. And there was a recognition as a company that we really need to be able to better speak the language of our customers in their respective industries. So the entire organization has really made a pivot to start to build that capability internally. That's part of the team that I support here at Snowflake. And with respect to healthcare and life sciences, that means being able to solve some of the challenges that Loick was just speaking about. In particular, we're seeing the industry evolve in a number of ways. You bring up clinical research in the time that it takes to actually bring a drug to market. This is a big one that's really changed a lot over the last couple of years. Some of the reasons are obvious and other ones are somewhat opportunistic. When we looked at what it takes to get a drug to market, there's several stages of clinical research that have to be participated in, and this can often take years. What we saw in the last couple of years is that all of a sudden patients didn't want to physically participate in those anymore because there was fear of potential infection and being in a healthcare facility. So the entire industry realized that it needed to change in terms of the way that it would engage with patients in that context. And we're now seeing this concept of decentralized clinical research. And with that becomes the need to potentially involve many different types of organizations beyond the traditional pharma, their research partners, but we're starting to see organizations like retail pharmacies, like big box retailers who have either healthcare delivery or pharmaceutical arms actually get involved in the process. And of course, one of the core things that happens here is that everyone needs a better way to collaborate and share data amongst one another. So bringing this back to your original question, this concept of being able to do exactly that is core to the healthcare and the life sciences data cloud to be able to collaborate and share data amongst those different types of organizations. Collaboration and data sharing, it seems to me to be a differentiator for Snowflake in terms of being able to deliver secure, governed, powerful analytics and data sharing to customers, to partners, to the ecosystem. You mentioned an example of the ecosystem there and how impactful to patients lives that collaboration and data sharing can be. It's absolutely right. It's something that if you think about all of the major challenges that the industry has had historically, whether it is high costs, whether it is health inequities, whether it is physicians practicing defensive medicine or repeat testing, what's core to each one of these things is kind of the inability to adequately collaborate and share data amongst all of the different players. So the industry has been waiting for the capability or some sort of solution to be able to do this, I think for a long, long time. And this is probably one of the most exciting parts of the conversations that we have with our customers is when they realize that this is possible. And not only that it's possible within our platform, but that most of the organizations that they work with today are also Snowflake customers. So they realize that everyone's already here, it's just a matter of who else can we work with and how do we get started? Join the party. Exactly. Lilik, talk to us about Novartis's data journey. I know you guys have been, I believe, using Snowflake since 2017, pre-pandemic. But you had a largely on-premises infrastructure. Talk to us about the decision of Novartis to go to the cloud, do it securely, and why you chose to partner with Snowflake. So when we started our journey in 2018, I think the ambition that CEO was to transform all enterprise processes for the use of digital tech. And at the core of this digital tech is a data foundation. So we started with a large program called Formula One, which aims to integrate all our internal and external data assets into an integrated platform. And through that, I think we've built this multi-cloud and best-of-brit platform where Snowflake is a core component. And we've been able to integrate almost 1,000 data assets, external and external through the platform, to be able to accelerate the use of data to create insight for our users. In that transformation, we've realized that Snowflake was could be a core component because of the scalability and the performance of with large data sets. And moreover, when Snowflake started to actually open collaboration for their marketplace, we've been able to integrate new data set that are publicly available at the place that we could not do on our own. So that is a core component of what we are trying to do. Yeah, and I think that's a great example of really what we're talking about here is that, he's mentioning that they're going out to our marketplace to be able to integrate data more easily with some of the vendors there. And that is kind of this concept of the healthcare and life sciences data cloud realized where all of a sudden acquiring and bringing data in and making it ready for analysis becomes much faster, much easier. And we continually see more and more vendors coming to us saying, I get it now, I want in. Who else can I work with in this space? So I think that's a perfect example of how this starts to become real for folks. When it sounds like the marketplace has been an enabler look of the expansion of use cases, this is, you've grown this beyond drug development. I read that you're developing new products and services for healthcare providers to personalize treatments for patients, which we all are demanding patients, but we want that personalized care. But talk about the marketplace as a facilitator of those expanding use cases that Snowflake is empowering. Yes, I mean, we have currently almost 65 use cases in production and we are in advanced progress for another 200 use cases. And they go across all the business sector. So if you look at drug development, we are monitoring our clinical trials using Snowflake. If you look at our omni-channel marketing, we are looking at personalization of information with our HEPs and HCOs using Snowflake. If you look at our manufacturing process, we are looking at yet management, freight optimization, inventory, insight. So almost across all the industry sector that we have, I think we are using the platforms to be able to deliver faster information to our users. And that's what we all want, faster information. Nobody, I think in the pandemic, we learned that access to real-time data in every industry wasn't a nice to have. That was an absolute necessity. And that made the difference for companies that survived and thrived and those that didn't. That's something that we learned. But we also learned that the volume of data just continues to proliferate. Loic, you've been in the industry a couple of decades. What do you see, and you've got obviously this great foundation now with Snowflake. You've got 65 use cases you set in production. What's the future of the data culture in healthcare and life sciences from your perspective? So my perspective, it is time now we give the access to our business technologies to be able to be self-sufficient using digital product. We need to consumerize the digital technology so they can be self-sufficient. The amount of problem that we have to solve and we can now solve with new technology has never been there. And I think we are in the past where in the next few years that you will see an accelerated generation of insight and an accelerated process of medicine by empowering the business technologies to use a technology that likes Snowflake and offers progress. What are your thoughts, Loic, of some of the obviously a lot of news coming out yesterday from Snowflake. We mentioned Standing Room only in the keynote. This I believe is north of 10,000 attendees. People are ready to engage in person with Snowflake. But some of the news coming out, what is your perspective? You've been a partner of theirs for a while. What do you see from Snowflake in terms of the news, the volume of customers it's adding, all that good stuff? I must say I was blown away yesterday when Frank was talking about the ramp up of customers using Snowflake, I think. But also I think in Benua and Christian and they talk about the innovation, when you look at the native application or you look at hybrid tables, these are things that end the expansion of the marketplace by monetization application. That is something that is going to accelerate the expansion not only on the company but the integration and the monetization of customers. And to Jesse's point, I think that it is key that people collaborate using the platform. I think we want to collaborate with suppliers and providers and they want to collaborate with us but we want to have a neutral environment where we can do that. And Snowflake can be that environment. And do it securely, right? Security is absolutely- Of course, that's really table stakes for this industry. And I think the point that you just made, Loic, is very important is that the biggest question that we're often asked by our customers is who else is a customer within this industry that I can collaborate with? I think as Loic will attest to, one of the challenges within life sciences in particular is that it is a highly regulated industry. It is a highly competitive industry. And folks are very sensitive about referenceability, so about things like logo usage. So to give some ideas here, people often have no idea that we're working with 28 of the top 50 global pharma today, working with seven of the top 12 global medical device companies today. The largest CRO is the largest distributors. So when I say that the party is here, they really are. And that's why we're so excited to have events like these. Because people can physically introduce themselves to one another and meet and actually start to engage in some of these more collaborative discussions that they've been waiting for. Justy, what's been some of the feedback that you've heard the last couple of days on the healthcare and life sciences data cloud? You've obviously finally gotten back to engaging with customers in person, but what are some of the things the feed on the street have said that you've done? We made the absolute right decision on this pivot. Yeah, well, I think some of it speaks to the point I was just speaking about is that they had no idea that so many of their peers were actually working with Snowflake already and how mature their implementations have actually been. The other thing that folks are realizing is that a lot of the technologies that serve this ecosystem, whether they're in the health tech space, whether they are clinical management or commercial engagement or supply chain planning technologies, those companies are also now pivoting to Snowflake where they're either building a part or the entirety of their platform on top of ours. So it offers this great way to start to collaborate with the ecosystem through some of those capabilities that we spoke about. And that's driving new use cases in commercial, in supply chain, in pharmacovigilance, in clinical operations. Well, I think you just summed up beautifully why the theme of this conference is the world of data collaboration. Yes, absolutely. The potential there that Snowflake is unleashing to the world is, I think is what's captivating to me, that you just scratch on the surface about connecting and facilitating this collaboration and this data sharing in a secure way across industries. Loic, last question for you. Take us home with what is next for Novartis. You've done a tremendous amount of digitalization. 65 use cases in production with Snowflake. What's next for the company? I think that in next year's to come, open collaboration with the ecosystem, but also personalization. We didn't, if you look at digital medicine and access to patients' information, you know. I think this is probably the next revolution that we are entering into. Excellent, and of course those demanding patients aren't going to want anything slower or less information. Guys, thank you for joining me on the program, talking about the Novartis-Snowflake collaboration, the partnership, the outcomes that you're achieving and how this is really dramatically impacting the lives of hundreds of millions of people. We appreciate your time and your insights. Thank you for having us, this was fun. My pleasure. Thank you. For my guests, I'm Lisa Martin. You're watching theCUBE. This is live from Las Vegas, day two of our coverage of Snowflake Summit 22. I'll be right back with my next guest, so stick around.